Genmab — November 2016
-
-
Pressemeddelelsen af 3. nov peger på de 4 vigtigste emner: Nøgle abstracts om daratumumab: Yderligere fase III data fra studierne CASTOR og POLLUX, fase I studie med subkutan formulering, immunmodulerende virkningsmekanismer og "real-life" kliniske genbehandlingsdata for daratumumab og pomalidomid.
-
Kære læser. Det er i strid med lov om ophavsret at kopiere og videresende artikler uden brug af det officielle link: http://borsen.dk/nyheder/virksomheder/artikel/1/335723/finanshus_partner_kan_lure_paa_opkoeb_af_genmab.html#ixzz4RJO32B1j
"Jefferies vurderer, at selskabet er lige knap 100 mia. kr. værd, hvis risikoen tages ud af de projekter, selskabet arbejder med i øjeblikket."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind